FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Feb 19, 2026
Spyre Therapeutics, Inc. (SYRE) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $155.2 million.
Revenue
$0
Net income
$-155.20M
+25.4% vs prior year
Operating cash flow (TTM)
$-249.32M
-54.0% vs year-ago TTM
Free cash flow
$-157.41M
-57.6% vs prior year
EPS
$13.76
+155.3% vs prior year
Dividend per share
None
Shares outstanding
78.54M
+30.3% vs prior year
Net cash
$339.28M
FY 2023
Operating margin
-27348.0%
FY 2023
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SYRE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1636282
- Former names
- Aeglea BioTherapeutics, Inc. (until Nov 24, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $886,000 | $2.3M | $18.7M |
| Operating income | -$209.6M | -$208.6M | -$242.3M | -$84.8M | -$65.6M |
| Net income | -$155.2M | -$208.0M | -$338.8M | -$83.8M | -$65.8M |
| Diluted EPS | — | — | $13.76 | -$24.86 | — |
| Operating cash flow | -$169.3M | -$157.4M | -$99.9M | -$80.1M | -$53.7M |
| Free cash flow | — | -$157.4M | -$99.9M | -$80.2M | -$54.3M |
| Total assets | $777.8M | $608.5M | $341.9M | $71.1M | $109.9M |
| Total liabilities | $62.5M | $90.7M | $73.3M | $20.8M | $26.0M |
| Stockholders' equity | $715.2M | $517.8M | $184.0M | $50.3M | $83.9M |
| Cash and investments | $756.5M | $603.1M | $339.3M | $55.7M | $93.1M |
| Total debt | — | — | $0 | $4.6M | $5.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 7, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 25, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
All 823 Spyre Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.